Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML

Oncotarget
Hamid SayarH Scott Boswell

Abstract

Co-occurrence of Flt3ITD and TET2 mutations provoke an animal model of AML by epigenetic repression of Wnt pathway antagonists, including RUNX3, and by hyperexpression of ID1, encoding Wnt agonist. These affect HOXA over-expression and treatment resistance. A comparable epigenetic phenotype was identified among adult AML patients needing novel intervention. We chose combinations of targeted agents acting on distinct effectors, at the levels of both signal transduction and chromatin remodeling, in relapsed/refractory AML's, including Flt3ITD+ve, described with a signature of repressed tumor suppressor genes, involving Wnt antagonist RUNX3, occurring along with ID1 and HOXA over-expressions. We tracked patient response to combination of Flt3/Raf inhibitor, Sorafenib, and Vorinostat, pan-histone deacetylase inhibitor, without or with added Bortezomib, in consecutive phase I trials. A striking association of rapid objective remissions (near-complete, complete responses) was noted to accompany induced early pharmacodynamic changes within patient blasts in situ, involving these effectors, significantly linking RUNX3/Wnt antagonist de-repression (80%) and ID1 downregulation (85%), to a response, also preceded by profound HOXA9 repress...Continue Reading

References

Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Oct 27, 2009·Molecular Cell·Chunaram ChoudharyHubert Serve
Aug 28, 2010·Leukemia & Lymphoma·Elizabeth A GriffithsHetty E Carraway
Nov 12, 2010·The New England Journal of Medicine·Timothy J LeyRichard K Wilson
Jul 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hiroto InabaSharyn D Baker
Aug 30, 2011·Nature Medicine·Kolja EppertJohn E Dick
Oct 26, 2011·International Journal of Cancer. Journal International Du Cancer·Hani RayessEri S Srivatsan
Nov 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rajasubramaniam ShanmugamH Scott Boswell
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Oct 6, 2012·The Journal of Biological Chemistry·Ling BeiElizabeth A Eklund
Aug 10, 2013·EMBO Molecular Medicine·Jung Eun ParkQi Zeng
Nov 26, 2013·Nature Genetics·Mira JeongMargaret A Goodell

❮ Previous
Next ❯

Methods Mentioned

BETA
RNAseq
bone marrow aspiration
PCR

Software Mentioned

RQ manager

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.

© 2022 Meta ULC. All rights reserved